Abstract
The Psoriasis Area and Severity Index (PASI) is the most widely used clinical measure in clinical trials to assess disease severity of plaque psoriasis. However, the PASI is not a precise measure of severity with less precision when the regional area of involvement is < 10% of the BSA of a specific anatomical region. Degradation of precision results from the area score defaulting to ‘1’ when the area of involvement within an anatomical region falls between 0% and 10% of the BSA for a given anatomical region. We describe a modification to the PASI, termed PASI-high discrimination (PASI-HD), for determination of more accurate psoriasis severity in body regions where < 10% of the body surface area is affected. The methodology for assessing disease severity in these conditions is described.
| Original language | English |
|---|---|
| Pages (from-to) | 1079-1083 |
| Number of pages | 5 |
| Journal | Dermatology and Therapy |
| Volume | 11 |
| Issue number | 4 |
| DOIs |
|
| State | Published - Aug 2021 |
Keywords
- Low body surface area
- Methodology
- PASI
- PASI-HD
- Plaque psoriasis
- Severity
Access to Document
Fingerprint
Dive into the research topics of 'The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Dermatology and Therapy, Vol. 11, No. 4, 08.2021, p. 1079-1083.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
AU - Papp, Kim A.
AU - Lebwohl, Mark G.
AU - Kircik, Leon H.
AU - Pariser, David M.
AU - Strober, Bruce
AU - Krueger, Gerald G.
AU - Berk, David R.
AU - Navale, Lynn
AU - Higham, Robert C.
N1 - Funding Information: Kim A. Papp: is an investigator, consultant, speaker, scientific officer or has served on steering committees or advisory boards for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermira, Dow Pharmaceuticals Sciences, Inc., Eli Lilly, Evelo, Galderma, Galpagos, Genentech, Gilead, GSK, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, and UCB Pharma. Mark G. Lebwohl: reports receipt of research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Pharma and serves as a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Inc., Avotres Therapeutics, BirchBioMed Inc., BMD skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, Neuroderm, Pfizer, Promius/Dr. Reddy’s Laboratories, Serono, Theravance, and Verrica. Leon H. Kircik: is an investigator, consultant, speaker, and/or advisory board member for Abbott Laboratories, Acambis, Aclaris, Allergan, Inc., Almirall, Amgen Inc., Anacor Pharmaceuticals, Assos Pharma, Astellas Pharma US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biogen Idec, Biolife, Biopelle, Boehringer Ingelheim, Breckinridge Pharma, Colbar, Celgene, Centocor, Inc., Cellceutix, Cipher, Coherus, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermavant, Dermira, Dermik Laboratories, Dow Pharmaceutical Sciences, Inc., Dusa, Eli Lilly, Embil Pharmaceuticals, EOS, Exeltis, Ferndale Laboratories, Inc., Foamix, Genentech, Inc., GlaxoSmithKline, PLC, Health Point, LTD, Idera, Intendis, Innocutis, Innovail, Isdin, Johnson & Johnson, Laboratory Skin Care Inc., LEO Pharma, L'Oreal, 3M, Maruho, Medical International Technologies, Merck, Medicis Pharmaceutical Corp., Merz, Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp., Obagi, Onset, OrthoNeutrogena, Promius, PediaPharma, QLT, Inc., PharmaDerm, Pfizer, PuraCap, Quinnova, Quatrix, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Sun Pharma, Taro, TolerRx, Triax, UCB Pharma, Valeant Pharmaceuticals Intl, Warner-Chilcott, XenoPort, and ZAGE. David M. Pariser: is an investigator, consultant, and/or advisory board member for Abbott Laboratories, Almirall, Amgen, AOBiome, LLC, Asana Biosciences, LLC, Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Bristol Myers Squibb, Celgene, Dermavant, Dermira, Eli Lilly and Company, LEO Pharma, US, Menlo Therapeutics, Merck & Co., Inc, Novartis Pharmaceuticals Corp., Novo Nordisk A/S, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Stiefel, a GSK company, TDM SurgiTech, Inc., TheraVida, and Valeant Pharmaceuticals International. Bruce Strober: is a consultant (honoraria) for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Dermira, Equillium, Janssen, LEO Pharma, Eli Lilly, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, and Sanofi-Genzyme, and a speaker for AbbVie, Amgen, Eli Lilly, Janssen, and Sanofi-Genzyme. He is also a Co-scientific Director (consulting fee) for Corrona Psoriasis Registry and an investigator for Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara Therapeutics, Novartis. He is Editor-in-Chief (honorarium) for Journal of Psoriasis and Psoriatic Arthritis. Gerald G. Krueger: is a consultant or advisory board member for Abbott, Amgen, Janssen Biotech, Eli Lilly, Novartis, Pfizer, Johnson & Johnson (PSOLAR), Sun Pharma, and DermTech International. He has received lecture fees from Abbott, Amgen, Janssen Biotech, Novartis, and Eli Lilly. David R. Berk: Employee of Arcutis Biotherapeutics, Inc. Lynn Navale: was an employee of Arcutis Biotherapeutics, Inc. at the time this manuscript was written and approved for submission. Robert C. Higham: Employee and stockholder of Arcutis Biotherapeutics, Inc. Funding Information: Medical writing support was provided by Susan Sutch, PharmD, of Alligent Biopharm Consulting LLC, funded by Arcutis Biotherapeutics. Publisher Copyright: © 2021, The Author(s).
PY - 2021/8
Y1 - 2021/8
N2 - The Psoriasis Area and Severity Index (PASI) is the most widely used clinical measure in clinical trials to assess disease severity of plaque psoriasis. However, the PASI is not a precise measure of severity with less precision when the regional area of involvement is < 10% of the BSA of a specific anatomical region. Degradation of precision results from the area score defaulting to ‘1’ when the area of involvement within an anatomical region falls between 0% and 10% of the BSA for a given anatomical region. We describe a modification to the PASI, termed PASI-high discrimination (PASI-HD), for determination of more accurate psoriasis severity in body regions where < 10% of the body surface area is affected. The methodology for assessing disease severity in these conditions is described.
AB - The Psoriasis Area and Severity Index (PASI) is the most widely used clinical measure in clinical trials to assess disease severity of plaque psoriasis. However, the PASI is not a precise measure of severity with less precision when the regional area of involvement is < 10% of the BSA of a specific anatomical region. Degradation of precision results from the area score defaulting to ‘1’ when the area of involvement within an anatomical region falls between 0% and 10% of the BSA for a given anatomical region. We describe a modification to the PASI, termed PASI-high discrimination (PASI-HD), for determination of more accurate psoriasis severity in body regions where < 10% of the body surface area is affected. The methodology for assessing disease severity in these conditions is described.
KW - Low body surface area
KW - Methodology
KW - PASI
KW - PASI-HD
KW - Plaque psoriasis
KW - Severity
UR - http://www.scopus.com/inward/record.url?scp=85109722838&partnerID=8YFLogxK
U2 - 10.1007/s13555-021-00572-2
DO - 10.1007/s13555-021-00572-2
M3 - Comment/debate
AN - SCOPUS:85109722838
SN - 2190-9172
VL - 11
SP - 1079
EP - 1083
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 4
ER -